About the job
Kardigan is dedicated to transforming heart health by developing treatments aimed at preventing and curing cardiovascular disease. The company’s mission is to end cardiovascular disease as the world’s leading cause of death.
Multiple targeted therapies are in development, with a focus on delivering effective solutions for people affected by cardiovascular conditions. Kardigan’s leadership includes Tassos Gianakakos, Jay Edelberg, M. D., Ph. D., and Bob McDowell, Ph. D. This team previously led MyoKardia, where their work resulted in the discovery of mavacamten, the first cardiac myosin inhibitor, and culminated in MyoKardia’s acquisition by Bristol Myers Squibb in 2020.
With a modern research platform and a strong pipeline of late-stage candidates, Kardigan is positioned to improve outcomes for patients living with heart disease.
Values
- Patient-centric: Every decision prioritizes patients and their families.
- Authenticity: The culture encourages acceptance and values each individual.
- Curiosity: Ongoing learning and openness to new perspectives are encouraged.
- Team success: Collaboration, urgency, and shared achievement are essential for results.
- Enable the impossible: Innovation and thoughtful risk-taking drive scientific advancement.
These values shape daily work and support Kardigan’s efforts to make a lasting difference in heart health.
